We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 135.60
Bid: 135.60
Ask: 136.20
Change: -2.40 (-1.74%)
Spread: 0.60 (0.442%)
Open: 140.20
High: 140.20
Low: 135.00
Prev. Close: 138.00
ELM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Trading Statement

29 Apr 2020 07:00

RNS Number : 2351L
Elementis PLC
29 April 2020
 

Elementis plc

AGM Trading Statement

Solid first quarter performance

Proactive measures taken to mitigate Covid-19 impact

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues a trading update for the three months ended 31 March 2020.

First quarter business performance

In the first quarter of 2020, trading has been in line with expectations, with year on year operating profit growth. Our global supply chain operated well with no raw material shortages or plant shutdowns except for, as previously announced, a temporary closure of two sites in China during February.

· Personal Care performance was modestly ahead of the prior year period, with resilient Cosmetics performance. AP Actives was stable with good volume growth offset by year on year pricing impacts.

 

· Coatings revenue grew with strong volumes in Asia and the Americas driven by new business wins and good momentum at global key accounts. Margins improved materially driven by cost savings, an improved product portfolio and lower raw material costs.

 

· Talc performance was broadly in line with the prior year period as robust sales in plastics and coatings were offset by lower ceramics and paper sales.

 

· Energy had a challenging start to the year with deteriorating market conditions only partially offset by strong global key account sales.

 

· Chromium sales were in line with the prior year period but margins declined due to lower pricing, notably outside of North America.

 

Liquidity and balance sheet

 

Elementis has a proven cash generative business model, with average operating cash conversion of 90% over the last 3 years. In addition, the Group continues to have significant liquidity, with in total over $300m immediately available through committed lending facilities. Total net debt for the Group (excluding lease liabilities under IFRS 16) was $454m at 31 December 2019, representing a ratio of 2.7x EBITDA* compared to a recently relaxed banking covenant of 3.75x*, which will apply for the next two testing periods (i.e. 30 June 2020 and 31 December 2020).

 

Proactive Covid-19 measures

 

To safely service customer demand the company has taken proactive steps to protect its people and maintain operations during the Covid-19 situation. The company's 22 operating sites continue to operate well, with the exception of a two week shutdown of our Palmital (Brazil) site in April. Construction of our new site in Mumbai, India, has been temporarily stopped due to government restrictions on operations.

 

In addition to the previously announced suspension of the 2019 final dividend, saving approximately $33m, and the temporary relaxation of banking covenants, the Group has taken the following further actions:

 

· Stopping all discretionary spend

· Reducing manufacturing costs based on lower demand

· Identifying additional working capital reductions

 

 

Outlook

 

Although first quarter trading was in line with expectations with improved profitability, the macro-economic and end-market outlook is highly uncertain and we have seen an approximate 15% year on year decline in April revenue. Given the uncertain environment no specific guidance is provided for the remainder of the year, although we will update as and when visibility improves. We continue to tightly and actively manage the business in terms of costs and cash flow to address changes in demand.

 

 

Commenting on the performance, CEO, Paul Waterman said,

"Elementis has a high quality, advantaged portfolio in premium performance additives with good long term growth opportunities. While our Q1 business performance was in line with expectations, the macro-economic and end-market outlook over the coming months is very uncertain. Having agreed a relaxation of our banking covenants and suspended our dividend to strengthen our financial position, our focus remains on what we can control, namely managing our operations well and optimising both cost and cash management."

 

Directorate change

Sandra Boss, Non-Executive Director has notified the Board that she wishes to retire from the Board to take up a full-time executive role. Sandra has served as a non-executive director and member of the audit, nomination and remuneration committees since February 2017 and in 2019, Sandra was appointed as designated non-executive director for engagement with the Company's workforce. A selection process for an additional Non-Executive Director has commenced.

 

Accordingly, Resolution 6 as set out in the Company's Notice of Annual General Meeting dated 19 March 2020 relating to Sandra's re-election as a director will be withdrawn. The withdrawal of this resolution does not affect the validity of the proxy form circulated to shareholders in respect of the 2020 Annual General Meeting or any proxy votes already submitted.

 

 

Enquiries

Elementis plc

James Curran, Investor Relations Tel: 020 7067 2994

 

Tulchan

Martin Robinson/David Allchurch Tel: 020 7353 4200

 

Notes

* Pre IFRS-16

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKVLFLBZLFBBX
Date   Source Headline
12th Apr 202411:33 amRNSDirector/PDMR Shareholding
12th Apr 202411:28 amRNSDirector/PDMR Shareholding
9th Apr 20246:04 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSAnnual Financial Report & Notice of AGM
19th Mar 20243:02 pmRNSAdditional Listing
15th Mar 20241:00 pmRNSDirectorate Change
12th Mar 20244:38 pmRNSDirector/PDMR Shareholding
12th Mar 20244:33 pmRNSDirector/PDMR Shareholding
8th Mar 20245:56 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSDirectorate changes
7th Mar 20247:00 amRNSPreliminary results year ended 31 December 2023
1st Mar 20249:30 amRNSBlock listing Interim Review
18th Jan 20247:00 amRNSTrading Update
2nd Jan 20249:45 amRNSTotal Voting Rights
1st Dec 202310:46 amRNSTotal Voting Rights
30th Nov 20239:38 amRNSDirector/PDMR Shareholding
14th Nov 20237:00 amRNS2023 Capital Markets Day
1st Nov 20239:46 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSThird Quarter Trading Update
2nd Oct 20239:34 amRNSTotal Voting Rights
20th Sep 202312:09 pmRNSResponse to open letter from Franklin Templeton
12th Sep 20233:13 pmRNSDirector Declaration
8th Sep 20239:30 amRNSHolding(s) in Company
1st Sep 20239:49 amRNSBlock listing Interim Review
1st Sep 20239:42 amRNSTotal Voting Rights
1st Aug 20239:44 amRNSTotal Voting Rights
27th Jul 20232:16 pmRNSHolding(s) in Company
27th Jul 20237:00 amRNSHalf-year Report
20th Jul 202312:58 pmRNSHolding(s) in Company
3rd Jul 202310:21 amRNSTotal Voting Rights
29th Jun 20234:29 pmRNSDirector/PDMR Shareholding
23rd Jun 20239:32 amRNSDirector/PDMR Shareholding
30th May 20238:06 amRNSDirector Declaration
2nd May 20239:37 amRNSTotal Voting Rights
26th Apr 20232:12 pmRNSResult of AGM
26th Apr 20237:00 amRNSAGM Trading Statement
17th Apr 202310:15 amRNSDirector/PDMR Shareholding
17th Apr 202310:10 amRNSDirector/PDMR Shareholding
13th Apr 20234:24 pmRNSDirector/PDMR Shareholding
3rd Apr 202311:28 amRNSDirector Declaration
3rd Apr 20239:34 amRNSTotal Voting Rights
24th Mar 20239:27 amRNSDirector/PDMR Shareholding
22nd Mar 20234:02 pmRNSAnnual Financial Report & Notice of AGM
17th Mar 20232:58 pmRNSAdditional Listing
14th Mar 20237:30 amRNSDirector Declaration
9th Mar 20232:50 pmRNSDirector/PDMR Shareholding
9th Mar 20232:47 pmRNSDirector/PDMR Shareholding
7th Mar 20237:00 amRNSPreliminary results year ended 31 December 2022
1st Mar 20239:53 amRNSBlock listing Interim Review
1st Mar 20239:39 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.